CLRB · Cellectar Biosciences Inc
United States · RS rating 9 · As of 2026-11-03
| Price | 1.31 USD |
|---|---|
| 1-day change | +7.4% |
| RS rating (overall / 1M / 3M / 12M) | 9 / 20 / 9 / 16 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 24 / 4 / 51 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +57.1% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +67.6% |
| Market cap (USD) | $11.8M |